Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $14.1M | $7,846.0K | $27.6M | $34.4M | $3,919.0K | $9,265.0K | $169.9M | $94.5M | $297.1M | $354.9M | $511.5M | $753.8M | $1,105.7M | $1,536.2M | $1,881.9M | $2,158.8M | $2,666.7M | $2,986.3M | $3,394.6M | $3,695.6M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Incyte Corporation's last 12-month Revenue is $4,075.9M, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Incyte Corporation's Revenue growth was 12.9%. The average annual Revenue growth rates for Incyte Corporation have been 14.7% over the past three years, 14.1% over the past five years.
Over the last year, Incyte Corporation's Revenue growth was 12.9%, which is higher than industry growth of 3.1%. It indicates that Incyte Corporation's Revenue growth is Good.